Starna offers new photometric linearity reference sets

Published: 13-May-2010

Suitable for pharmaceutical QA laboratories

Starna Scientific’s near infrared (NIR) traceable photometric linearity reference sets are now available for pharmaceutical QA labs and customer support organisations seeking to qualify their NIR systems. These reference sets offer Operational Qualification (OQ) and Performance Qualification (PQ) of the transmittance scale in the NIR using industry standard protocols.

The sets are based on easy to handle, non-consumable Certified Reference Materials for qualifying the NIR Transmittance scale. The wavelength range covered is 1100 to 2850nm, with a %T (A) range of 1.5 %T (1.82A) to 61%T (0.21A).

Starna, based in Hainault, Essex, UK, has many years of experience gained preparing Visible Neutral Density filter references for ISO 17025 and ISO Guide 34 accreditation and produces references for National Measurement Institutions (NMIs).

See more

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Read more
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    NICE approval is not enough: why the UK’s next medicines challenge is operational delivery A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR
  2. Strengthening US pharmaceutical supply: SCHOTT Pharma inaugurates expanded vial production in Lebanon, PA SCHOTT Pharma has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs — from biologics and other complex injectable therapies to vaccines and emergency room medications
  3. Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
  4. Ardena appoints Ariane de Ganck as Chief Scientific Officer Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and complex therapies, today announced the appointment of Ariane de Ganck, PhD, as Chief Scientific Officer
  5. Compact, economical and sustainable cooling solutions for laboratories Huber Unichillers offer space-saving and environmentally friendly temperature control for research and industrial applications

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Drug Delivery

Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies

The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Finance

UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures

Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines
You need to be a subscriber to read this article.
Click here to find out more.
Finance

ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum

From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
Subscribe now